Roles for lysophospholipid S1P receptors in multiple sclerosis

References

• Abbott NJ, Ronnback L and Hansson E. 2006. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7:41–53.
   PubMed Web of Science ®Google Scholar
• Adachi K, Kohara T, Nakao N, Arita M, Chiba K, Mishina T, Sasaki S and Fujita T. 1995. Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: discovery of a novel immunosuppressant, FTY720. Bioorg Med Chem Lett 5:853–856.
   Web of Science ®Google Scholar
• Allende ML, Yamashita T and Proia RL. 2003. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood 102:3665–3667.
   PubMed Web of Science ®Google Scholar
• Allende ML, Dreier JL, Mandala S and Proia RL. 2004. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem 279:15396–15401.
   PubMed Web of Science ®Google Scholar
• Allende ML, Tuymetova G, Lee BG, Bonifacino E, Wu YP and Proia RL. 2010. S1P1 receptor directs the release of immature B cells from bone marrow into blood. J Exp Med 207:1113–1124.
   Web of Science ®Google Scholar
• Alvarez SE, Milstien S and Spiegel S. 2007. Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endocrinol Metab 18:300–307.
   PubMed Web of Science ®Google Scholar
• Anelli V, Bassi R, Tettamanti G, Viani P and Riboni L. 2005. Extracellular release of newly synthesized sphingosine-1-phosphate by cerebellar granule cells and astrocytes. J Neurochem 92:1204–1215.
   PubMed Web of Science ®Google Scholar
• Bassi R, Anelli V, Giussani P, Tettamanti G, Viani P and Riboni L. 2006. Sphingosine-1-phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi-protein-coupled receptors. Glia 53:621–630.
   Google Scholar
• Billich A, Bornancin F, Devay P, Mechtcheriakova D, Urtz N and Baumruker T. 2003. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 278:47408–47415.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Chen S, Feng L, Pinschewer D, Nikolova Z and Hof R. 2001. FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transplant Proc 33:530–531.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR. 2002. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453–21457.
   PubMed Web of Science ®Google Scholar
• Budde K, Schutz M, Glander P, Peters H, Waiser J, Liefeldt L, Neumayer HH and Bohler T. 2006. FTY720 (fingolimod) in renal transplantation. Clin Transplant 20 Suppl 17:17–24.
   Google Scholar
• Chiba K, Yanagawa Y, Masubuchi Y, Kataoka H, Kawaguchi T, Ohtsuki M and Hoshino Y. 1998. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 160:5037–5044.
   PubMed Web of Science ®Google Scholar
• Chun J and Hartung HP. 2010. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33:91–101.
   PubMed Web of Science ®Google Scholar
• Cinamon G, Zachariah MA, Lam OM, Foss FW Jr and Cyster JG. 2008. Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat Immunol 9:54–62.
   PubMed Web of Science ®Google Scholar
• Coelho RP, Payne SG, Bittman R, Spiegel S and Sato-Bigbee C. 2007. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 323:626–635.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. 2010. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402–415.
   PubMed Web of Science ®Google Scholar
• Correale J and Villa A. 2007. The blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targeting. Autoimmunity 40:148–160.
   PubMed Web of Science ®Google Scholar
• Cuzner ML and Opdenakker G. 1999. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J Neuroimmunol 94:1–14.
   PubMed Web of Science ®Google Scholar
• Czeloth N, Bernhardt G, Hofmann F, Genth H and Forster R. 2005. Sphingosine-1-phosphate mediates migration of mature dendritic cells. J Immunol 175:2960–2967.
   PubMed Web of Science ®Google Scholar
• Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hoyer D and Mir A. 2008. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 117:77–93.
   PubMed Web of Science ®Google Scholar
• Dudek SM, Camp SM, Chiang ET, Singleton PA, Usatyuk PV, Zhao Y, Natarajan V and Garcia JG. 2007. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. Cell Signal 19:1754–1764.
   PubMed Web of Science ®Google Scholar
• Edsall LC, Pirianov GG and Spiegel S. 1997. Involvement of sphingosine 1-phosphate in nerve growth factor-mediated neuronal survival and differentiation. J Neurosci 17:6952–6960.
   PubMed Web of Science ®Google Scholar
• Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, Reuschel R, Beerli C, Schwartz M and Billich A. 2007. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 323:469–475.
   PubMed Web of Science ®Google Scholar
• Foster CA, Mechtcheriakova D, Storch MK, Balatoni B, Howard LM, Bornancin F, Wlachos A, Sobanov J, Kinnunen A and Baumruker T. 2009. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol 19:254–266.
   PubMed Web of Science ®Google Scholar
• Frohman EM, Racke MK and Raine CS. 2006. Multiple sclerosis – the plaque and its pathogenesis. N Engl J Med 354:942–955.
   PubMed Web of Science ®Google Scholar
• Fujino M, Funeshima N, Kitazawa Y, Kimura H, Amemiya H, Suzuki S and Li XK. 2003. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 305:70–77.
   PubMed Web of Science ®Google Scholar
• Graler MH and Goetzl EJ. 2004. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 18:551–553.
   PubMed Web of Science ®Google Scholar
• Harada J, Foley M, Moskowitz MA and Waeber C. 2004. Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J Neurochem 88:1026–1039.
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Suzuki H, Sozen T, Rolland W and Zhang JH. 2010. Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke 41:368–374.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group. 2008. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688.
   PubMed Web of Science ®Google Scholar
• Ishii I, Fukushima N, Ye X and Chun J. 2004. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 73:321–354.
   PubMed Web of Science ®Google Scholar
• Jack C, Ruffini F, Bar-Or A and Antel JP. 2005. Microglia and multiple sclerosis. J Neurosci Res 81:363–373.
   PubMed Web of Science ®Google Scholar
• Jaillard C, Harrison S, Stankoff B, Aigrot MS, Calver AR, Duddy G, Walsh FS, Pangalos MN, Arimura N, Kaibuchi K, Zalc B, Lubetzki C. 2005. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci 25:1459–1469.
   PubMed Web of Science ®Google Scholar
• Jenne CN, Enders A, Rivera R, Watson SR, Bankovich AJ, Pereira JP, Xu Y, Roots CM, Beilke JN, Banerjee A, Reiner SL, Miller SA, Weinmann AS, Goodnow CC, Lanier LL, Cyster JG, Chun J. 2009. T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. J Exp Med 206:2469–2481.
   PubMed Web of Science ®Google Scholar
• Jung CG, Kim HJ, Miron VE, Cook S, Kennedy TE, Foster CA, Antel JP and Soliven B. 2007. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 55:1656–1667.
   PubMed Web of Science ®Google Scholar
• Kabashima K, Haynes NM, Xu Y, Nutt SL, Allende ML, Proia RL and Cyster JG. 2006. Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism. J Exp Med 203:2683–2690.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P. FREEDOMS Study Group. 2010. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387–401.
   PubMed Web of Science ®Google Scholar
• Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A and Chiba K. 2005. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2:439–448.
   PubMed Web of Science ®Google Scholar
• Kimura A, Ohmori T, Ohkawa R, Madoiwa S, Mimuro J, Murakami T, Kobayashi E, Hoshino Y, Yatomi Y and Sakata Y. 2007. Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 25:115–124.
   PubMed Web of Science ®Google Scholar
• Kunisawa J, Kurashima Y, Gohda M, Higuchi M, Ishikawa I, Miura F, Ogahara I and Kiyono H. 2007. Sphingosine 1-phosphate regulates peritoneal B-cell trafficking for subsequent intestinal IgA production. Blood 109:3749–3756.
   Google Scholar
• Lan YY, De Creus A, Colvin BL, Abe M, Brinkmann V, Coates PT and Thomson AW. 2005. The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am J Transplant 5:2649–2659.
   PubMed Web of Science ®Google Scholar
• Lee JF, Zeng Q, Ozaki H, Wang L, Hand AR, Hla T, Wang E and Lee MJ. 2006. Dual roles of tight junction-associated protein, zonula occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity. J Biol Chem 281:29190–29200.
   PubMed Web of Science ®Google Scholar
• Lee KD, Chow WN, Sato-Bigbee C, Graf MR, Graham RS, Colello RJ, Young HF and Mathern BE. 2009. FTY720 reduces inflammation and promotes functional recovery after spinal cord injury. J Neurotrauma 26:2335–2344.
   Google Scholar
• Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, Volpi M, Sha’afi RI and Hla T. 1999. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 99:301–312.
   PubMed Web of Science ®Google Scholar
• Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W, Rosen H. 2002. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346–349.
   PubMed Web of Science ®Google Scholar
• Martin R. 2010. Multiple sclerosis: closing in on an oral treatment. Nature 464:360–362.
   PubMed Web of Science ®Google Scholar
• Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL and Cyster JG. 2004. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427:355–360.
   PubMed Web of Science ®Google Scholar
• McGiffert C, Contos JJ, Friedman B and Chun J. 2002. Embryonic brain expression analysis of lysophospholipid receptor genes suggests roles for s1p(1) in neurogenesis and s1p(1-3) in angiogenesis. FEBS Lett 531:103–108.
   PubMed Web of Science ®Google Scholar
• McLaughlin KA and Wucherpfennig KW. 2008. B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol 98:121–149.
   Google Scholar
• Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RL and Kappos L. 2008. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 71:1261–1267.
   PubMed Web of Science ®Google Scholar
• Meno-Tetang GM, Li H, Mis S, Pyszczynski N, Heining P, Lowe P and Jusko WJ. 2006. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos 34:1480–1487.
   PubMed Web of Science ®Google Scholar
• Miller RH and Mi S. 2007. Dissecting demyelination. Nat Neurosci 10:1351–1354.
   PubMed Web of Science ®Google Scholar
• Miron VE, Hall JA, Kennedy TE, Soliven B and Antel JP. 2008. Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod. Am J Pathol 173:1143–1152.
   PubMed Web of Science ®Google Scholar
• Miron VE, Ludwin SK, Darlington PJ, Jarjour AA, Soliven B, Kennedy TE and Antel JP. 2010. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol 176:2682–2694.
   PubMed Web of Science ®Google Scholar
• Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S and Proia RL. 2005. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 25:11113–11121.
   PubMed Web of Science ®Google Scholar
• Morandi B, Bramanti P, Bonaccorsi I, Montalto E, Oliveri D, Pezzino G, Navarra M and Ferlazzo G. 2008. Role of natural killer cells in the pathogenesis and progression of multiple sclerosis. Pharmacol Res 57:1–5.
   Google Scholar
• Muller H, Hofer S, Kaneider N, Neuwirt H, Mosheimer B, Mayer G, Konwalinka G, Heufler C and Tiefenthaler M. 2005. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol 35:533–545.
   PubMed Web of Science ®Google Scholar
• Mullershausen F, Craveiro LM, Shin Y, Cortes-Cros M, Bassilana F, Osinde M, Wishart WL, Guerini D, Thallmair M, Schwab ME, Sivasankaran R, Seuwen K, Dev KK. 2007. Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J Neurochem 102:1151–1161.
   PubMed Web of Science ®Google Scholar
• Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D and Seuwen K. 2009. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 5:428–434.
   PubMed Web of Science ®Google Scholar
• Nair A, Frederick TJ and Miller SD. 2008. Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci 65:2702–2720.
   PubMed Web of Science ®Google Scholar
• Nayak D, Huo Y, Kwang WX, Pushparaj PN, Kumar SD, Ling EA and Dheen ST. 2010. Sphingosine kinase 1 regulates the expression of proinflammatory cytokines and nitric oxide in activated microglia. Neuroscience 166:132–144.
   PubMed Web of Science ®Google Scholar
• Novgorodov AS, El-Alwani M, Bielawski J, Obeid LM and Gudz TI. 2007. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J 21:1503–1514.
   PubMed Web of Science ®Google Scholar
• Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR, Lin CY and Hla T. 2007. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 282:9082–9089.
   PubMed Web of Science ®Google Scholar
• Osinde M, Mullershausen F and Dev KK. 2007. Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology 52:1210–1218.
   PubMed Web of Science ®Google Scholar
• Papadopoulos D, Rundle J, Patel R, Marshall I, Stretton J, Eaton R, Richardson JC, Gonzalez MI, Philpott KL and Reynolds R. 2010. FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. J Neurosci Res 88:346–359.
   Google Scholar
• Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E, Zheng YW, Huang Y, Cyster JG, Coughlin SR. 2007. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 316:295–298.
   PubMed Web of Science ®Google Scholar
• Paugh SW, Payne SG, Barbour SE, Milstien S and Spiegel S. 2003. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 554:189–193.
   PubMed Web of Science ®Google Scholar
• Pebay A, Toutant M, Premont J, Calvo CF, Venance L, Cordier J, Glowinski J and Tence M. 2001. Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades. Eur J Neurosci 13:2067–2076.
   Web of Science ®Google Scholar
• Peng X, Hassoun PM, Sammani S, McVerry BJ, Burne MJ, Rabb H, Pearse D, Tuder RM and Garcia JG. 2004. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med 169:1245–1251.
   PubMed Web of Science ®Google Scholar
• Pham TH, Baluk P, Xu Y, Grigorova I, Bankovich AJ, Pappu R, Coughlin SR, McDonald DM, Schwab SR and Cyster JG. 2010. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J Exp Med 207:17–27.
   PubMed Web of Science ®Google Scholar
• Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H and Zinkernagel RM. 2000. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 164:5761–5770.
   PubMed Web of Science ®Google Scholar
• Rao TS, Lariosa-Willingham KD, Lin FF, Palfreyman EL, Yu N, Chun J and Webb M. 2003. Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes. Brain Res 990:182–194.
   PubMed Web of Science ®Google Scholar
• Rao TS, Lariosa-Willingham KD, Lin FF, Yu N, Tham CS, Chun J and Webb M. 2004. Growth factor pre-treatment differentially regulates phosphoinositide turnover downstream of lysophospholipid receptor and metabotropic glutamate receptors in cultured rat cerebrocortical astrocytes. Int J Dev Neurosci 22:131–135.
   PubMed Web of Science ®Google Scholar
• Riboni L, Viani P, Bassi R, Giussani P and Tettamanti G. 2000. Cultured granule cells and astrocytes from cerebellum differ in metabolizing sphingosine. J Neurochem 75:503–510.
   Google Scholar
• Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, Claffey K and Hla T. 2003. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 278:47281–47290.
   PubMed Web of Science ®Google Scholar
• Schaphorst KL, Chiang E, Jacobs KN, Zaiman A, Natarajan V, Wigley F and Garcia JG. 2003. Role of sphingosine-1 phosphate in the enhancement of endothelial barrier integrity by platelet-released products. Am J Physiol Lung Cell Mol Physiol 285:L258–267.
   PubMed Web of Science ®Google Scholar
• Schwab SR and Cyster JG. 2007. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 8:1295–1301.
   PubMed Web of Science ®Google Scholar
• Sensken SC, Bode C and Graler MH. 2009. Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy. J Pharmacol Exp Ther 328:963–969.
   PubMed Web of Science ®Google Scholar
• Slavin A, Kelly-Modis L, Labadia M, Ryan K and Brown ML. 2010. Pathogenic mechanisms and experimental models of multiple sclerosis. Autoimmunity 47(7):1–10.
   Google Scholar
• Sorensen SD, Nicole O, Peavy RD, Montoya LM, Lee CJ, Murphy TJ, Traynelis SF and Hepler JR. 2003. Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol Pharmacol 64:1199–1209.
   PubMed Web of Science ®Google Scholar
• Strochlic L, Dwivedy A, van Horck FP, Falk J and Holt CE. 2008. A role for S1P signalling in axon guidance in the Xenopus visual system. Development 135:333–342.
   Google Scholar
• Tedesco-Silva H, Mourad G, Kahan BD, Boira JG, Weimar W, Mulgaonkar S, Nashan B, Madsen S, Charpentier B, Pellet P, Vanrenterghem Y. 2005. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 79:1553–1560.
   PubMed Web of Science ®Google Scholar
• Terai K, Soga T, Takahashi M, Kamohara M, Ohno K, Yatsugi S, Okada M and Yamaguchi T. 2003. Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS. Neuroscience 116:1053–1062.
   PubMed Web of Science ®Google Scholar
• Tham CS, Lin FF, Rao TS, Yu N and Webb M. 2003. Microglial activation state and lysophospholipid acid receptor expression. Int J Dev Neurosci 21:431–443.
   PubMed Web of Science ®Google Scholar
• Toman RE, Payne SG, Watterson KR, Maceyka M, Lee NH, Milstien S, Bigbee JW and Spiegel S. 2004. Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. J Cell Biol 166:381–392.
   PubMed Web of Science ®Google Scholar
• Walzer T, Chiossone L, Chaix J, Calver A, Carozzo C, Garrigue-Antar L, Jacques Y, Baratin M, Tomasello E and Vivier E. 2007. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol 8:1337–1344.
   PubMed Web of Science ®Google Scholar
• Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, Andersson PB, Stabler G and Miller K. 1999. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 53:1397–1401.
   PubMed Web of Science ®Google Scholar
• Webb M, Tham CS, Lin FF, Lariosa-Willingham K, Yu N, Hale J, Mandala S, Chun J and Rao TS. 2004. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 153:108–121.
   PubMed Web of Science ®Google Scholar
• Weiner JA, Hecht JH and Chun J. 1998. Lysophosphatidic acid receptor gene vzg-1/lpA1/edg-2 is expressed by mature oligodendrocytes during myelination in the postnatal murine brain. J Comp Neurol 398:587–598.
   PubMedGoogle Scholar
• Williams A, Piaton G and Lubetzki C. 2007. Astrocytes – friends or foes in multiple sclerosis? Glia 55:1300–1312.
   PubMed Web of Science ®Google Scholar
• Wu YP, Mizugishi K, Bektas M, Sandhoff R and Proia RL. 2008. Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease. Hum Mol Genet 17:2257–2264.
   PubMed Web of Science ®Google Scholar
• Xie JH, Nomura N, Koprak SL, Quackenbush EJ, Forrest MJ and Rosen H. 2003. Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells. J Immunol 170:3662–3670.
   PubMed Web of Science ®Google Scholar
• Yamagata K, Tagami M, Torii Y, Takenaga F, Tsumagari S, Itoh S, Yamori Y and Nara Y. 2003. Sphingosine 1-phosphate induces the production of glial cell line-derived neurotrophic factor and cellular proliferation in astrocytes. Glia 41:199–206.
   PubMed Web of Science ®Google Scholar
• Yu N, Lariosa-Willingham KD, Lin FF, Webb M and Rao TS. 2004. Characterization of lysophosphatidic acid and sphingosine-1-phosphate-mediated signal transduction in rat cortical oligodendrocytes. Glia 45:17–27.
   PubMed Web of Science ®Google Scholar
• Zemann B, Kinzel B, Muller M, Reuschel R, Mechtcheriakova D, Urtz N, Bornancin F, Baumruker T and Billich A. 2006. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 107:1454–1458.
   PubMed Web of Science ®Google Scholar
• Zhang YH, Vasko MR and Nicol GD. 2006. Intracellular sphingosine 1-phosphate mediates the increased excitability produced by nerve growth factor in rat sensory neurons. J Physiol 575:101–113.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Fauser U, Artelt M, Burnet M and Schluesener HJ. 2007. FTY720 attenuates accumulation of EMAP-II+ and MHC-II+ monocytes in early lesions of rat traumatic brain injury. J Cell Mol Med 11:307–314.
   Google Scholar
• Zhu D, Wang Y, Singh I, Bell RD, Deane R, Zhong Z, Sagare A, Winkler EA and Zlokovic BV. 2010. Protein S controls hypoxic/ischemic blood-brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor. Blood 115:4963–4972.
   Google Scholar